Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 1, 2013, Pages 55-61

  Cuzzocrea, Salvatore ^a   Esposito, Emanuela ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Glial cells; N acylethanolamine; Neuroprotection; Spinal cord

Indexed keywords

CANNABINOID 2 RECEPTOR; PALMIDROL;

APOPTOSIS; ASTROCYTOSIS; BRAIN EDEMA; BRAIN INFARCTION; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; GLIA; HOMEOSTASIS; HUMAN; MYELITIS; NECROSIS; NERVE CELL PLASTICITY; NERVE COMPRESSION; NERVE DEGENERATION; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NOCICEPTION; NONHUMAN; PAIN; REVIEW; TISSUE INJURY; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; ENDOCANNABINOIDS; ETHANOLAMINES; HOMEOSTASIS; HUMANS; NEUROGLIA; NEUROPROTECTIVE AGENTS; PALMITIC ACIDS; SPINAL CORD INJURIES;

EID: 84875338025     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312010010     Document Type: Review

References (94)

1. S.P.H. N-Palmitoylethanolamine. In: Enna, S.J.; Bylund D.B. xPharm: The Comprehensive Pharmacology Reference". 2009, Elsevier, pp. 1-4
2. Petrosino, S.; Iuvone, T.; Di Marzo, V. N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie., 2010, 92(6), 724-727.
3. Re, G.; Barbero, R.; Miolo, A.; Di Marzo, V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Vet J., 2007, 173(1), 21-30.
4. Chapman, K.D. Occurrence, metabolism, and prospective functions of N-acylethanolamines in plants. Prog Lipid Res., 2004, 43(4), 302-327.
5. Petrosino, S.; Di Marzo, V. Anandamide and Other Acylethanolamides. Chapter 5 In: Tettamanti G and Goracci G (eds.), Handbook of neurochemistry and molecular neurobiology. Neural Lipids, 3rd edition, Springer, 2009, pp.75-98.
6. Bisogno, T.; Maurelli, S.; Melck, D.; De Petrocellis, L.; Di Marzo, V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem., 1997, 272(6), 3315-3323.
7. Jacobsson, S.O.; Fowler, C.J. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br. J. Pharmacol. 2001, 132(8), 1743-1754.
8. Coburn, A.F.; Graham, C.E.; Haninger, J. The effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. J. Exp. Med., 1954, 100(5), 425-435.
9. Long, D.A.; Martin, A.J. Factor in arachis oil depressing sensitivity to tuberculin in B.C.G.-infected guineapigs. Lancet., 1956, 270(6921), 464-466.
10. Kuehl, F.A.; Jacob, T.A.; Ganley, O.H.; Ormond, R.E.; Meisinger, M.A.P. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occuring anti-inflammatory agent. J. Am. Chem. Soc., 1957, 79(19), 5577-5578.
11. Ganley, O.H.; Graessle, O.E.; Robinson, H.J. Anti-inflammatory activity on compounds obtained from egg yolk, peanut oil, and soybean lecithin. J. Lab. Clin. Med., 1958, 51(5),709-714.
12. Benvenuti, F.; Lattanzi, F.; De Gori, A.; Tarli, P. Activity of some derivatives of palmitoylethanolamide on carragenine-induced edema in the rat paw. Boll. Soc. Ital. Biol. Sper., 1968, 44(9), 809-813.
13. Perlik, F.; Raskova, H.; Elis, J. Anti-inflammatory properties of N(2-hydroxyethyl) palmitamide. Acta Physiol. Acad. Sci. Hung., 1971, 39(4), 395-400.
14. Aloe, L.; Leon, A.; Levi-Montalcini, R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions., 1993, 3 (C), 145-147.
15. Ito, A.; Hagiyama, M.; Oonuma, J. Nerve-mast cell and smooth muscle-mast cell interaction mediated by cell adhesion molecule-1, CADM1. J. Smooth Muscle. Res., 2008, 44(2), 83-93.
16. Abraham, S.N.; St John, AL. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol., 2010, 10(6), 440-452.
17. Brown, J.M.; Wilson, T.M.; Metcalfe, D.D. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin. Exp. Allergy., 2008, 38(1), 4-18.
18. Kumar, V.; Sharma, A. Mast cells: Emerging sentinel innate immune cells with diverse role in immunity. Mol. Immunol., 2010, 48(1-3), 14-25.
19. Maurer, M.; Theoharides, T.; Granstein, R.D.; Bischoff, S.C.; Bienenstock, J.; Henz, B.; Kovanen, P.; Piliponsky, A.M.; Kambe, N.; Vliagoftis, H.; Levi-Schaffer, F.; Metz, M.; Miyachi, Y.; Befus, D.; Forsythe, P.; Kitamura, Y.; Galli, S. What is the physiological function of mast cells? Exp. Dermatol., 2003, 12(6), 886-910.
20. Metz, M.; Grimbaldeston, M.A.; Nakae, S.; Piliponsky, A.M.; Tsai, M.; Galli, S.J. Mast cells in the promotion and limitation of chronic inflammation. Immunol. Rev., 2007, 217, 304-328.
21. Moon, T.C.; St Laurent, C.D.; Morris, K.E.; Marcet, C.; Yoshimura, T.; Sekar, Y.; Befus, A.D. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol., 2010, 3(2), 111-128.
22. Lundequist, A.; Pejler, G. Biological implications of preformed mast cell mediators. Cell. Mol. Life Sci., 2011, 68(6), 965-975.
23. Bischoff, S.C. Physiological and pathophysiological functions of intestinal mast cells. Semin. Immunopathol., 2009, 31(2), 185-205.
24. Eklund, K.K. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev., 2007, 217, 38-52.
25. Harvima, I.T.; Nilsson, G.; Suttle, M.M.; Naukkarinen, A. Is there a role for mast cells in psoriasis? Arch. Dermatol. Res., 2008, 300(9), 461-478.
26. Holdsworth, S.R.; Summers, S.A. Role of Mast Cells in Progressive Renal Diseases. J. Am. Soc. Nephrol., 2008, 19(12), 2254-2261.
27. Nautiyal, K.M.; Ribeiro, A.C.; Pfaff, D.W.; Silver, R. Brain mast cells link the immune system to anxiety-like behavior. Proc. Natl. Acad. Sci. U S A., 2008, 105(46), 18053-18057.
28. Strbian, D.; Kovanen, P.T.; Karjalainen-Lindsberg, M.L.; Tatlisumak, T.; Lindsberg, P.J. An emerging role of mast cells in cerebral ischemia and hemorrhage. Ann. Med., 2009, 41, 438-450.
29. Facci, L.; Dal Toso, R.; Romanello, S.; Buriani, A.; Skaper, S.D.; Leon, A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci., 1995, 92(8), 3376-3380.
30. Lambert, D.M.; Vandevoorde, S.; Jonsson, K.O.; Fowler, C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr. Med. Chem., 2002, 9(6), 663-674.
31. Lambert, D.M.; Di Marzo, V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr. Med. Chem., 1999, 6(8), 757-773.
32. Showalter, V.M.; Compton, D.R.; Martin, B.R.; Abood, M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 1996, 278(3), 989-999.
33. Sugiura, T.; Kondo, S.; Kishimoto, S.; Miyashita, T.; Nakane, S.; Kodaka, T.; Suhara, Y.; Takayama, H.; Waku, K. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem., 2000, 275(1), 605-612.
34. Jaggar, S.I.; Hasnie, F.S.; Sellaturay, S.; Rice, A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain., 1998, 76(1-2), 189-199.
35. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature, 1998, 394(6690), 277-281.
36. Conti, S.; Costa, B.; Colleoni, M.; Parolaro, D.; Giagnoni, G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol., 2002, 135(1),181-187.
37. Naccarato, M.; Pizzuti, D.; Petrosino, S.; Simonetto, M.; Ferigo, L.; Chiodo Grandi, F.; Pizzolato, G.; Di Marzo, V. Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Lipids Health Dis., 2010, 9(1), 47.
38. Moriconi, A.; Cerbara, I.; Maccarrone, M.; Topai, A. GPR55: Current Knowledge and Future Perspectives of a Purported Type-3 Cannabinoid Receptor. Curr. Med. Chem., 2010, 17(14), 1411-1429.
39. LoVerme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol.,2005, 67(1), 15-19.
40. O'Sullivan, S.E.; Kendall, D.A. Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease. Immunobiology, 2010, 215(8), 611-616.
41. Cantarella, G.; Scollo, M.; Lempereur, L.; Saccani-Jotti, G.; Basile, F.; Bernardini, R. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem. Pharmacol., 2011, 82(4), 380-388.
42. Levi-Montalcini, R.; Skaper, S.D.; Dal Toso, R.; Petrelli, L.; Leon, A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci., 1996, 19(11), 514-520.
43. Annuzzi, G.; Piscitelli, F.; Di Marino, L.; Patti, L.; Giacco, R.; Costabile, G.; Bozzetto, L.; Riccardi, G.; Verde, R.; Petrosino, S.; Rivellese, A.A.; Di Marzo V. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis., 2010, 9, 43.
44. Schmid, P.C.; Krebsbach, R.J.; Perry, S.R.; Dettmer, T.M.; Maasson, J.L.; Schmid, H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett., 1995, 375(1-2), 117-120.
45. Capasso, R.; Izzo, A.A.; Fezza, F.; Pinto, A.; Capasso, F.; Mascolo, N.; Di Marzo, V. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br. J. Pharmacol., 2001, 134(5), 945-950.
46. D'Argenio, G.; Petrosino, S.; Gianfrani, C.; Valenti, M.; Scaglione, G.; Grandone, I.; Nigam, S.; Sorrentini, I.; Mazzarella, G.; Di Marzo, V. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J. Mol. Med., 2007, 85(5), 523-530.
47. Izzo, A.A.; Aviello, G.; Petrosino, S.; Orlando, P.; Marsicano, G.; Lutz, B.; Borrelli, F.; Capasso, R.; Nigam, S.; Capasso, F.; Di Marzo, V; Endocannabinoid Research Group. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J. Mol. Med., 2008, 86(1), 89-98.
48. Guindon, J.; LoVerme, J.; De Lean, A.; Piomelli, D.; Beaulieu, P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: A role for endogenous fatty-acid ethanolamides? Eur. J. Pharmacol., 2006, 550(1-3), 68-77.
49. Petrosino, S.; Cristino, L.; Karsak, M.; Gaffal, E.; Ueda, N.; Tüting, T.; Bisogno, T.; De Filippis, D.; D'Amico, A.; Saturnino, C.; Orlando, P.; Zimmer, A.; Iuvone, T.; Di Marzo, V. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy., 2010, 65(6), 698-711.
50. Matias, I.; Wang, J.W.; Moriello, A.S.; Nieves, A.; Woodward, D.F.; Di Marzo, V. Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukot. Essent. Fatty Acids., 2006, 75(6), 413-418.
51. Chen, J.; Matias, I.; Dinh, T.; Lu, T.; Venezia, S.; Nieves, A.; Woodward, D.F.; Di Marzo, V. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem. Biophys. Res. Commun., 2005, 330(4), 1062-1067.
52. Schreiber, D.; Harlfinger, S.; Nolden, B.M.; Gerth, C.W.; Jaehde, U.; Schomig, E.; Klosterkotter, J.; Giuffrida, A.; Astarita, G.; Piomelli, D.; Markus Leweke, F. Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal. Biochem., 2007, 361(2), 162-168.
53. Ozalp, A.; Barroso, B. Simultaneous quantitative analysis of n-acylethanolamides in clinical samples. Anal. Biochem., 2009, 395(1), 68-76.
54. Balvers, M.G.J.; Verhoeckx, K.C.M.; Witkamp, R.F. Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2009, 877(14-15), 1583-1590.
55. Jumpertz, R.; Guijarro, A.; Pratley, R.E.; Piomelli, D.; Krakoff, J. Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. J. Clin. Endocrinol. Metab., 2011, 96(3), 787-91.
56. Giuffrida, A.; Piomelli, D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett., 1998, 422(3), 373-376.
57. Richardson, D.; Pearson, R.G.; Kurian, N.; Latif, M.L.; Garle, M.J.; Barrett, D.A.; Kendall, D.A.; Scammell, B.E.; Reeve, A.J.; Chapman V. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther., 2008, 10(2), R43.
58. Petrosino, S.; Albanese, F.; Abramo, F.; Di Marzo, V. Increased skin levels of the aliamide palmitoylethanolamide and other endogenous fatty acid amides in dogs with atopic dermatitis. 33rd Annual WSAVA/FECAVA Congress, Dublin, Ireland, 20th-24th August 2008, p. 707.
59. Ghafouri, N; Ghafouri, B; Larsson, B; Turkina, MV.; Karlsson, L.; Fowler, CJ.; Gerdle, B. High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PLoS One., 2011, 6(11), e27257.
60. K.D. Emerging physiological roles for N-acylphosphatidylethanolamine metabolism in plants: signal transduction and membrane protection. Chem. Phys. Lipids., 2000, 108(1-2), 221-230.
61. Cerrato, S.; Brazis, P.; Miolo, A.; della Valle, MF.; Puigdemont, A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFa release from canine skin mast cells. Vet. Immunol. Immunopathol, 2010, 133(1), 9-15.
62. Hoareau, L.; Buyse, M.; Festy, F.; Ravanan, P.; Gonthier, M.P.; Matias, I.; Petrosino, S.; Tallet, F.; d'Hellencourt, C.L.; Cesari, M.; Di Marzo, V.; Roche, R. Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. Obesity, 2009, 17(3), 431-438.
63. Skaper, S.D.; Buriani, A.; Dal Toso, R; Petrelli, L.; Romanello, S.; Facci, L.; Leon, A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. U S A., 1996, 93(9), 3984-3989.
64. Costa, B.; Conti, S.; Giagnoni, G.; Colleoni, M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol, 2002, 137(4), 413-420.
65. Wise, L.E.; Cannavacciulo, R.; Cravatt, B.F.; Marun, B.F.; Lichtman, A.H. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology, 2008, 54(1), 181-188.
66. Guida, G.; de Martino, M.; de Fabiani, A.; Cantieri, L.; Alexandre, A.; Vassallo, G.M.; Rogai, M.; Lanaia, F.; Petrosino, S. La palmitoiletanolamida (Normast®) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo: estudio clínico multicéntrico. Dolor., 2010, 25, 35-42.
67. Conigliaro, R.; Drago, V.; Foster, P.S.; Schievano, C; Di Marzo, V. Use of the palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med., 2011, 102(2), 141-147.
68. Eberlein, B.; Eicke, C; Reinhardt, H.W.; Ring, J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J. Eur. Acad. Dermatol. Venereol, 2008;22(1), 73-82.
69. Artmann, A.; Petersen, G.; Hellgren, L.I.; Boberg, J.; Skonberg, C; Nellemann, C; Hansen, S.H.; Hansen, H.S. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim. Biophys. Acta., 2008, 1781(4), 200-212.
70. Muccioli, G.G.; Stella, N. An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain. Anal. Biochem., 2008, 373(2), 220-228.
71. Murillo-Rodriguez, E.; Désarnaud, F.; Prospéro-García, O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci., 2006, 79(1), 30-37.
72. Walter, L.; Franklin, A.; Witting, A.; Moller, T.; Stella, N. Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem., 2002, 277(23), 20869-20876.
73. Muccioli, G.G.; Stella, N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology, 2008, 54(1), 16-22.
74. Stella, N.; Piomelli, D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol, 2001, 425(3), 189-196.
75. Kallendrusch, S.; Koch, M.; Grabiec, U.; Dehghani, F. Perforant pathway transsection induces differntial regulation of endocannabinoid levels in organotypic hippocampal slice cultures. Proceedings ICRS 2010 - 20th Annual Symposium of the International Cannabinoid Research Society, 2010, Lund, Sweden.
76. Garcia-Ovejero, D.; Arevalo-Martin, A.; Petrosino, S.; Docagne, F.; Hagen, C.; Bisogno, T.; Watanabe, M.; Guaza, C.; Di Marzo, V.; Molina-Holgado, E. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol. Dis., 2009, 33(1), 57-71.
77. Franklin, A.; Parmentier-Batteur, S.; Walter, L.; Greenberg, DA.; Stella, N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci., 2003, 23(21), 7767-7775.
78. Berger, C.; Schmid, P.C.; Schabitz, W.R.; Wolf, M.; Schwab, S.; Schmid, H.H. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J. Neurochem., 2004, 88(5), 1159-1167.
79. Sheerin, A.H.; Zhang, X.; Saucier, D.M.; Corcoran, M.E. Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia., 2004, 45(10), 1184-1188.
80. Duncan, R.S.; Chapman, K.D.; Koulen, P. The neuroprotective properties of palmitoylethanolamine against oxidative stress in a neuronal cell line. Mol. Neurodegener., 2009, 4, 50.
81. Koch, M.; Kreutz, S.; Böttger, C.; Benz, A.; Maronde, E.; Ghadban, C.; Korf, H.W.; Dehghani, F. Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-alpha. Neurotox Res., 2011, 19(2), 330-340.
82. Natarajan, V.; Schmid, P.C.; Schmid, H.H. N-acylethanolamine phospholipid metabolism in normal and ischemic rat brain. Biochim. Biophys. Acta., 1986, 878(1), 32-41.
83. Petrosino, S.; Palazzo, E.; de Novellis, V.; Bisogno, T.; Rossi, F.; Maione, S.; Di Marzo, V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology, 2007, 52(2), 415-422.
84. Ben-Shabat, S.; Fride, E.; Sheskin, T.; Tamiri, T.; Rhee, M.H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di Marzo, V.; Mechoulam, R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol., 1998, 353(1), 23-31.
85. Genovese, T.; Esposito, E.; Mazzon, E.; Di Paola, R.; Meli, R.; Bramanti, P.; Piomelli, D.; Calignano, A.; Cuzzocrea, S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J. Pharmacol. Exp. Ther., 2008, 326(1), 12-23.
86. Esposito, E.; Paterniti, I.; Mazzon, E.; Genovese, T.; Di Paola, R.; Galuppo, M.; Cuzzocrea, S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav. Immun., 2011, 25(6), 1099-1112.
87. Scuderi, C; Esposito, G.; Blasio, A.; Valenza, M.; Arietti, P.; Steardo, L.; Carnuccio, R.; De Filippis, D.; Petrosino, S.; Iuvone, T.; Di Marzo, V.; Steardo, L. Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. J. Cell. Mol. Med., 2011, 15(12), 2664-2674.
88. Polazzi, E.; Gianni, T.; Contestabile, A. Microglial cells protect cerebellar granule neurons from apoptosis: evidence for reciprocal signaling. Glia., 2001, 36(3), 271-280.
89. Figueiredo, C; Pais, TF.; Gomes, JR.; Chatterjee, S. Neuron-microglia crosstalk up-regulates neuronal FGF-2 expression which mediates neuroprotection against excitotoxicity via JNK1/2. J. Neurochem., 2008, 107(1), 73-85.
90. Anderova, M.; Vorisek, I.; Pivonkova, H.; Benesova, J.; Vargova, L.; Cicanic, M.; Chvatal, A.; Sykova, E. Cell death/proliferation and alterations in glial morphology contribute to changes in diffusivity in the rat hippocampus after hypoxia-ischemia. J. Cereb. Blood Flow Metab., 2011, 31(3), 894-907.
91. Mattace Raso, G.; Esposito, E.; Vitiello, S.; Iacono, A.; Santoro, A.; D'Agostino, G.; Sasso, O.; Russo, R.; Piazza, PV.; Calignano, A.; Meli, R. Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-a. J. Neuroendocrinol., 2011, 23(7), 591-600.
92. Sasso, O.; Russo, R.; Vitiello, S.; Raso, GM.; D'Agostino, G.; Iacono, A.; Rana GL.; Vallée, M.; Cuzzocrea, S.; Piazza, PV.; Meli, R.; Calignano, A. Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain. Pain., 2012, 153(1), 33-41.
93. Sasso, O.; La Rana, G.; Vitiello, S.; Russo, R.; D'Agostino, G.; Iacono, A.; Russo, E.; Citraro, R.; Cuzzocrea, S.; Piazza, PV.; De Sarro, G.; Meli, R.; Calignano, A. Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice: involvement of allopregnanolone biosynthesis. Eur. Neuropsychopharmacol, 2010, 20(3), 195-206.
94. D'Agostino, G.; Russo, R.; Avagliano, C; Cristiano, C; Meli, R.; Calignano, A. Palmitoylethanolamide Protects Against the Amyloid-p25-35-Induced Learning and Memory Impairment in Mice, an Experimental Model of Alzheimer Disease. Neuropsychopharmacology, 2012, (7), 1784-1792.